• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . An autoimmunity-associated allele of PTPN22 enhances innate antiviral immunity to protect against acute coronavirus infe

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2026 Mar 24;123(12):e2519903123.
doi: 10.1073/pnas.2519903123. Epub 2026 Mar 18.
An autoimmunity-associated allele of PTPN22 enhances innate antiviral immunity to protect against acute coronavirus infection

Alec M Bevis[SUP] 1 [/SUP], Kathryn J L H Rosa[SUP] 1 [/SUP], Nancy Schwarting[SUP] 1 [/SUP], Tammy R Cockerham[SUP] 1 [/SUP], Catherine M Kerr[SUP] 1 [/SUP], Sunil More[SUP] 2 [/SUP], Anthony R Fehr[SUP] 1 [/SUP], Robin C Orozco[SUP] 1 [/SUP]


Affiliations
Abstract

Allelic variation can impact viral clearance and disease severity. Still, our understanding of the effect of the autoimmunity-associated allelic variant of Ptpn22 (PEP-R619W) on antiviral immunity remains incomplete, as previous reports have only focused on chronic lymphocytic choriomeningitis virus infection. This research defines how the loss of Ptpn22 (PEP-null) and PEP-R619W changes antiviral immunity during an acute coronavirus infection. We address the hypothesis that CRISPR/Cas9-generated PEP-null and PEP-R619W mice have enhanced antiviral immunity over PEP-wild-type (WT) mice during coronavirus infection. Following mouse hepatitis virus A59 infection, we interrogated pathology, cytokine production, and cellular responses in the blood, spleen, and liver of PEP-WT, PEP-null, and PEP-R619W mice. Key findings show that PEP-R619W mice have reduced viral titer and weight loss, increased survival, and more mature natural killer (NK) cells in the liver and spleen compared to PEP-WT mice. Interestingly, protection against disease in PEP-null mice was inoculation dose dependent, whereas PEP-R619W conferred immunity regardless of infection dose. Further, Rag1[SUP]-/-[/SUP] PEP-R619W mice had increased survival and reduced viral titer over Rag1[SUP]-/-[/SUP] PEP-WT mice. PEP-R619W mice also had higher concentrations of interferon-gamma (IFNγ) and enhanced IFNγ production by mature NK cells in the liver at 3 d postinfection. Finally, NK cell depletion elevated PEP-R619W viral titer to similar levels as PEP-WT mice. This study investigates the role of Ptpn22 within NK cells and demonstrates that the Ptpn22 allelic variant augments NK cell function and is beneficial during coronavirus infection.

Keywords: PTPN22; coronavirus; natural killer (NK) cells.

 
Back
Top Bottom